Raymond Hsu
@drraymondhsu.bsky.social
academic nephrologist | clinical investigator | learner & educator
ucsf nephrology
he/him | views=my own
ucsf nephrology
he/him | views=my own
Reposted by Raymond Hsu
In stable AKI patients, indication-based dialysis enabled faster liberation from dialysis and reduced health care resource use compared to conventional thrice-weekly treatment.
#KidneyWK @asnkidney.bsky.social
ja.ma/47GXUgm
#KidneyWK @asnkidney.bsky.social
ja.ma/47GXUgm
November 7, 2025 at 5:20 PM
In stable AKI patients, indication-based dialysis enabled faster liberation from dialysis and reduced health care resource use compared to conventional thrice-weekly treatment.
#KidneyWK @asnkidney.bsky.social
ja.ma/47GXUgm
#KidneyWK @asnkidney.bsky.social
ja.ma/47GXUgm
Reposted by Raymond Hsu
Trials coming out already!
jamanetwork.com/journals/jam...
Rituximab better than placebo in FRNS/SDNS
Duh.
#KidneyWk #NephSky
jamanetwork.com/journals/jam...
Rituximab better than placebo in FRNS/SDNS
Duh.
#KidneyWk #NephSky
November 5, 2025 at 8:33 PM
Trials coming out already!
jamanetwork.com/journals/jam...
Rituximab better than placebo in FRNS/SDNS
Duh.
#KidneyWk #NephSky
jamanetwork.com/journals/jam...
Rituximab better than placebo in FRNS/SDNS
Duh.
#KidneyWk #NephSky
Reposted by Raymond Hsu
“.. Since the pandemic, he has mostly lived on the Big Island of Hawaii, where he has bought up numerous parcels of land. He said that he wasn’t sure how many days he spends each year in San Francisco ..”
@nytimes.com $CRM
www.nytimes.com/2025/10/10/u...
@nytimes.com $CRM
www.nytimes.com/2025/10/10/u...
October 10, 2025 at 11:26 PM
“.. Since the pandemic, he has mostly lived on the Big Island of Hawaii, where he has bought up numerous parcels of land. He said that he wasn’t sure how many days he spends each year in San Francisco ..”
@nytimes.com $CRM
www.nytimes.com/2025/10/10/u...
@nytimes.com $CRM
www.nytimes.com/2025/10/10/u...
Reposted by Raymond Hsu
🎓 Congratulations to our 2025 Nephrology Fellowship Graduates! 🩺
We are proud to send off this exceptional group of nephrologists who are ready to make an impact wherever they go. Here’s to the next chapter in your careers—your patients (and their kidneys) are in great hands.
We are proud to send off this exceptional group of nephrologists who are ready to make an impact wherever they go. Here’s to the next chapter in your careers—your patients (and their kidneys) are in great hands.
July 1, 2025 at 4:28 PM
🎓 Congratulations to our 2025 Nephrology Fellowship Graduates! 🩺
We are proud to send off this exceptional group of nephrologists who are ready to make an impact wherever they go. Here’s to the next chapter in your careers—your patients (and their kidneys) are in great hands.
We are proud to send off this exceptional group of nephrologists who are ready to make an impact wherever they go. Here’s to the next chapter in your careers—your patients (and their kidneys) are in great hands.
Celebrating another successful year of our GN club with fellows and faculty @ucsfnephrology.bsky.social
June 24, 2025 at 3:54 AM
Celebrating another successful year of our GN club with fellows and faculty @ucsfnephrology.bsky.social
Reposted by Raymond Hsu
#ASNCJASN welcomes original kidney health-focused artwork submissions for consideration on future covers. Creative, thought-provoking pieces are sought to reflect the impact of kidney health on individuals and communities. Submit your artwork today at www.editorialmanager....
June 12, 2025 at 4:31 PM
#ASNCJASN welcomes original kidney health-focused artwork submissions for consideration on future covers. Creative, thought-provoking pieces are sought to reflect the impact of kidney health on individuals and communities. Submit your artwork today at www.editorialmanager....
Reposted by Raymond Hsu
Good write up of the @drraymondhsu.bsky.social et al BP trial in advanced CKD, on the @ajkd.bsky.social blog: ajkdblog.org/2025/05/28/e...
RCT here: www.ajkd.org/action/consu...
RCT here: www.ajkd.org/action/consu...
Exploring the Optimal Blood Pressure Target in Advanced CKD
Dr. Nozaina Mahmood is a Nephrology fellow at the University of Alabama at Birmingham with clinical and academic interests in chronic kidney disease, health disparities in nephrology, and evidence-…
ajkdblog.org
May 28, 2025 at 11:44 AM
Good write up of the @drraymondhsu.bsky.social et al BP trial in advanced CKD, on the @ajkd.bsky.social blog: ajkdblog.org/2025/05/28/e...
RCT here: www.ajkd.org/action/consu...
RCT here: www.ajkd.org/action/consu...
Reposted by Raymond Hsu
This #AAPIHeritageMonth, we’re raising awareness of how lupus impacts the AAPI community and why understanding health disparities is critical to creating change. Learn more: buff.ly/0I73RQ8
May 4, 2025 at 9:00 PM
This #AAPIHeritageMonth, we’re raising awareness of how lupus impacts the AAPI community and why understanding health disparities is critical to creating change. Learn more: buff.ly/0I73RQ8
Reposted by Raymond Hsu
The Asian American and Pacific Islander (AAPI) community encompasses diverse cultures and languages. They face a disproportionate burden with #lupus. Lupus-related death rates among Hispanic and Asian women are 4–6 times higher than the general population.
May 4, 2025 at 9:00 PM
The Asian American and Pacific Islander (AAPI) community encompasses diverse cultures and languages. They face a disproportionate burden with #lupus. Lupus-related death rates among Hispanic and Asian women are 4–6 times higher than the general population.
Reposted by Raymond Hsu
The @nytimes.com with @danagoldstein.bsky.social cover the story of Dr Rasha Alawieh being deported despite the Judge’s order (gift link)
(She’s a nephrologist, not a surgeon, but that doesn’t matter here)
www.nytimes.com/2025/03/16/u...
(She’s a nephrologist, not a surgeon, but that doesn’t matter here)
www.nytimes.com/2025/03/16/u...
Brown University Surgeon and Professor Are Deported to Lebanon Despite a Judge’s Order (Gift Article)
Dr. Rasha Alawieh, a kidney transplant specialist and Brown University professor who had a valid visa, was expelled in apparent defiance of a court order.
www.nytimes.com
March 16, 2025 at 7:54 PM
The @nytimes.com with @danagoldstein.bsky.social cover the story of Dr Rasha Alawieh being deported despite the Judge’s order (gift link)
(She’s a nephrologist, not a surgeon, but that doesn’t matter here)
www.nytimes.com/2025/03/16/u...
(She’s a nephrologist, not a surgeon, but that doesn’t matter here)
www.nytimes.com/2025/03/16/u...
Reposted by Raymond Hsu
#NephMadness 2025 is live on the #AJKDBlog: bit.ly/WelcomeNM25
Topics include:
- Resistant Hypertension
- Obesity
- Green House
- Minimal Change Disease
- Disaster Nephrology
- Genetics
- Hemodialysis
- CAR-T for Kidney Disease
Looking forward to the fun and learning with all of you!
Topics include:
- Resistant Hypertension
- Obesity
- Green House
- Minimal Change Disease
- Disaster Nephrology
- Genetics
- Hemodialysis
- CAR-T for Kidney Disease
Looking forward to the fun and learning with all of you!
Welcome to #NephMadness 2025
Here it is, the 13th edition of NephMadness! Whether you’re new to the competition or just want to relive past glories, we have all the info you need for NephMadness 2025: What is NephMadnes…
buff.ly
March 3, 2025 at 1:17 PM
#NephMadness 2025 is live on the #AJKDBlog: bit.ly/WelcomeNM25
Topics include:
- Resistant Hypertension
- Obesity
- Green House
- Minimal Change Disease
- Disaster Nephrology
- Genetics
- Hemodialysis
- CAR-T for Kidney Disease
Looking forward to the fun and learning with all of you!
Topics include:
- Resistant Hypertension
- Obesity
- Green House
- Minimal Change Disease
- Disaster Nephrology
- Genetics
- Hemodialysis
- CAR-T for Kidney Disease
Looking forward to the fun and learning with all of you!
Reposted by Raymond Hsu
It is a full fledge assault on medical research. Turning off funding, canceling grants, and disabling the tools we use. It is a complete dismantling of the infrastructure.
March 2, 2025 at 1:16 AM
It is a full fledge assault on medical research. Turning off funding, canceling grants, and disabling the tools we use. It is a complete dismantling of the infrastructure.
Reposted by Raymond Hsu
We urge the Administration and Congress to reconsider and roll back these actions immediately so potential cuts can be made in a thoughtful and safer manner. To do otherwise may result in absolute tragedy for the American people.
NKF Statement on Mass Staff Terminations at HHS
www.kidney.org
February 18, 2025 at 9:01 PM
We urge the Administration and Congress to reconsider and roll back these actions immediately so potential cuts can be made in a thoughtful and safer manner. To do otherwise may result in absolute tragedy for the American people.
Reposted by Raymond Hsu
In a prespecified interim analysis of a phase 3, randomized, controlled trial, the selective endothelin type A receptor antagonist atrasentan reduced proteinuria in patients with IgA nephropathy, without apparent safety issues. Full ALIGN trial results: nej.md/3NzvISW
#MedSky #Nephrology
#MedSky #Nephrology
February 11, 2025 at 8:26 PM
In a prespecified interim analysis of a phase 3, randomized, controlled trial, the selective endothelin type A receptor antagonist atrasentan reduced proteinuria in patients with IgA nephropathy, without apparent safety issues. Full ALIGN trial results: nej.md/3NzvISW
#MedSky #Nephrology
#MedSky #Nephrology
Reposted by Raymond Hsu
In the REGENCY trial, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, plus standard therapy provided significantly better renal responses than standard therapy alone in patients with lupus nephritis. Full trial results: nej.md/3Eq6gxV
#ISNWCN | @theisn.org
#ISNWCN | @theisn.org
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM
Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly
better renal responses than placebo in a phase 2 trial involving patients with lupus
nephritis receiving stan...
nej.md
February 7, 2025 at 2:15 PM
In the REGENCY trial, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, plus standard therapy provided significantly better renal responses than standard therapy alone in patients with lupus nephritis. Full trial results: nej.md/3Eq6gxV
#ISNWCN | @theisn.org
#ISNWCN | @theisn.org
Reposted by Raymond Hsu
Today is Retraction Day, when we observe the anniversary of the retraction (Feb. 2, 2010) of the fraudulent paper that purported to show a link between vaccines and autism. 🧪#medsky
![This is the front page of a fraudulent research article that purported to show a link between vaccines and autism. The word "RETRACTED" is written across it in large red letters.
Wikipedia: On 28th February 1998, a fraudulent research paper by physician Andrew Wakefield and twelve coauthors, titled "Ileal-Lymphoid-Nodular Hyperplasia, Non-Specific Colitis, and Pervasive Developmental Disorder in Children", was published in the British medical journal The Lancet.[1] The paper falsely claimed causative links between the measles, mumps, and rubella (MMR) vaccine and colitis and between colitis and autism. The fraud involved data selection, data manipulation, and two undisclosed conflicts of interest.](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:sox6xar4qdc3ujhi5h4whtlh/bafkreiazjyxk6foryp6lzxcqbls62uaokwhjrjmnzg5uqpdimg77xrt26a@jpeg)
February 2, 2025 at 2:25 PM
Today is Retraction Day, when we observe the anniversary of the retraction (Feb. 2, 2010) of the fraudulent paper that purported to show a link between vaccines and autism. 🧪#medsky
Reposted by Raymond Hsu
BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
www.cnbc.com
January 28, 2025 at 8:21 PM
BREAKING NEWS: The FDA has approved Ozempic for patients with chronic kidney disease. This means the popular injection can be used to reduce the risk of kidney disease worsening, kidney failure and death from cardiovascular disease in patients with chronic kidney disease and diabetes.
Reposted by Raymond Hsu
Reposted by Raymond Hsu
Infamous Phantom Nephro Recs:
1. Avoid nephrotoxins (pt needs atbxs + CTA)
2. Keep MAP >65 (on the floor, not on pressors)
3. Trend Cr daily (already ✔️BMPs q 8h happening)
4. Strict I/Os (on diapers, refuses Foley/PureWick)
5. Renally dose all meds (pt not on any renally cleared med)
1. Avoid nephrotoxins (pt needs atbxs + CTA)
2. Keep MAP >65 (on the floor, not on pressors)
3. Trend Cr daily (already ✔️BMPs q 8h happening)
4. Strict I/Os (on diapers, refuses Foley/PureWick)
5. Renally dose all meds (pt not on any renally cleared med)
a man in a black shirt says " don 't do this " in white letters
ALT: a man in a black shirt says " don 't do this " in white letters
media.tenor.com
December 18, 2024 at 6:18 PM
Infamous Phantom Nephro Recs:
1. Avoid nephrotoxins (pt needs atbxs + CTA)
2. Keep MAP >65 (on the floor, not on pressors)
3. Trend Cr daily (already ✔️BMPs q 8h happening)
4. Strict I/Os (on diapers, refuses Foley/PureWick)
5. Renally dose all meds (pt not on any renally cleared med)
1. Avoid nephrotoxins (pt needs atbxs + CTA)
2. Keep MAP >65 (on the floor, not on pressors)
3. Trend Cr daily (already ✔️BMPs q 8h happening)
4. Strict I/Os (on diapers, refuses Foley/PureWick)
5. Renally dose all meds (pt not on any renally cleared med)
Reposted by Raymond Hsu
An opposing view would be to throw caution to the wind and implement GDMT at a more accelerated rate similar to CHF
journals.lww.com/cjasn/fullte...
@asnkidney.bsky.social #CJASN
@brendonneuen.bsky.social
#NephJC
journals.lww.com/cjasn/fullte...
@asnkidney.bsky.social #CJASN
@brendonneuen.bsky.social
#NephJC
December 18, 2024 at 2:50 AM
An opposing view would be to throw caution to the wind and implement GDMT at a more accelerated rate similar to CHF
journals.lww.com/cjasn/fullte...
@asnkidney.bsky.social #CJASN
@brendonneuen.bsky.social
#NephJC
journals.lww.com/cjasn/fullte...
@asnkidney.bsky.social #CJASN
@brendonneuen.bsky.social
#NephJC
Reposted by Raymond Hsu
It has taken more than 4 years but the methodologically poor (doi.org/10.1016/j.th...) and questionable paper (1-day peer review bmcmedresmethodol.bi...) that promoted HCQ for COVID-19 is finally retracted. We've been saying for years it had to be (doi.org/10.1016/j.th...).
December 17, 2024 at 10:06 AM
It has taken more than 4 years but the methodologically poor (doi.org/10.1016/j.th...) and questionable paper (1-day peer review bmcmedresmethodol.bi...) that promoted HCQ for COVID-19 is finally retracted. We've been saying for years it had to be (doi.org/10.1016/j.th...).
Reposted by Raymond Hsu
So very happy with this publication! I hope it will assist trainees in #nephrology and #renalpath in the uses of IF.
karger.com/gdz/article/...
karger.com/gdz/article/...
Immunofluorescence Use and Techniques in Glomerular Diseases: A Review
Abstract. Background: Immunofluorescence (IF) studies play an essential role in the evaluation of medical renal biopsies. Particularly, in the study of renal glomerular diseases, where it provides fun...
karger.com
December 13, 2024 at 2:04 PM
So very happy with this publication! I hope it will assist trainees in #nephrology and #renalpath in the uses of IF.
karger.com/gdz/article/...
karger.com/gdz/article/...
Celebrating the holidays with @ucsfnephrology.bsky.social GN Club including several alumni of our fellowship GN track
December 10, 2024 at 4:29 AM
Celebrating the holidays with @ucsfnephrology.bsky.social GN Club including several alumni of our fellowship GN track
Reposted by Raymond Hsu
Women as leaders bring many benefits!!
December 9, 2024 at 12:52 AM
Women as leaders bring many benefits!!
Reposted by Raymond Hsu
Our own @drraymondhsu.bsky.social speaking on IgA nephropathy and lupus nephritis
Really excited. Thank you for all the support. 🥰
438 total
137 in-person
301 virtual
Still have time to register until midnight 👇
www.eeds.com/portal_live_...
438 total
137 in-person
301 virtual
Still have time to register until midnight 👇
www.eeds.com/portal_live_...
December 7, 2024 at 11:18 PM
Our own @drraymondhsu.bsky.social speaking on IgA nephropathy and lupus nephritis